Company profile: Adocia
1.1 - Company Overview
Company description
- Provider of biotechnology therapies specializing in tissue regeneration and diabetes treatments, developing medicines with already-approved therapeutic proteins. Offerings include BioChaperone Lispro ultra-rapid insulin, BioChaperone Combo glargine+lispro, AdoShell Islets hydrogel implant, M1Pram and BioChaperone LisPram co-formulations, and AdOral Sema oral semaglutide.
Products and services
- AdoShell Islets: A hydrogel-based implant containing islets of Langerhans engineered for cell therapy against type 1 diabetes, delivering an islet-containing device for therapeutic intervention
- BioChaperone Combo: A clinical-grade fixed combination of long-acting insulin glargine and rapid-acting insulin lispro for type 2 diabetes treatment in a single co-formulated product
- BioChaperone Lispro: A clinical-grade ultra-rapid prandial insulin lispro formulation engineered for better management of blood glucose levels during meals
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adocia
Kaleido
HQ: The Netherlands
Website
- Description: Provider of wearable insulin pump solutions for diabetes management, including the Kaleido insulin pump delivering continuous fast-acting insulin over 24 hours with hourly adjustments, connecting via a tube and infusion set and wearable up to three days; the Kaleido with Diabeloop’s DBLG1 Hybrid Closed Loop using Dexcom G6 and a handheld device to auto-adjust dosing; and a starter kit with two reusable pumps, a handset, training and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleido company profile →
Vitae Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies, building a portfolio of novel, best-in-class small molecules and biologics addressing significant unmet needs, including chronic kidney disease, diabetes, atherosclerosis, and Alzheimer’s. Programs span immunology, oncology, neuroscience, eye care, aesthetics, and patient access and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitae Pharmaceuticals company profile →
Sensulin
HQ: United States
Website
- Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensulin company profile →
Intuity Medical
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems for diabetes management, featuring the POGO Automatic Monitor that automatically lances, collects blood, and provides results with a single press using 10-test cartridges that integrate lancets and test strips, and the Patterns app to sync, track, visualize trends, share readings, send emergency notifications, and integrate with other health apps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intuity Medical company profile →
Generex
HQ: United States
Website
- Description: Provider of drug delivery systems and technologies for metabolic and immunological diseases, developing and commercializing these offerings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adocia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adocia
2.2 - Growth funds investing in similar companies to Adocia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adocia
4.2 - Public trading comparable groups for Adocia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →